Angela M. Nilius
Infectious Diseases Research
Abbott Laboratories
Abbott Park
Illinois 60064-3500
USA
Name/email consistency: high
- Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class. Nilius, A.M. Curr. Opin. Investig. Drugs (2003)
- In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Nilius, A.M., Shen, L.L., Hensey-Rudloff, D., Almer, L.S., Beyer, J.M., Balli, D.J., Cai, Y., Flamm, R.K. Antimicrob. Agents Chemother. (2003)
- Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. Nilius, A.M., Hensey-Rudloff, D.M., Reimann, M.A., Flamm, R.K. J. Antimicrob. Chemother. (2002)
- Ketolides: the future of the macrolides?. Nilius, A.M., Ma, Z. Curr. Opin. Pharmacol (2002)
- Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Nilius, A.M., Bui, M.H., Almer, L., Hensey-Rudloff, D., Beyer, J., Ma, Z., Or, Y.S., Flamm, R.K. Antimicrob. Agents Chemother. (2001)
- In vitro activity of A-192411.29, a novel antifungal lipopeptide. Nilius, A.M., Raney, P.M., Hensey-Rudloff, D.M., Wang, W., Li, Q., Flamm, R.K. Antimicrob. Agents Chemother. (2000)
- Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. Nilius, A.M., Beyer, J.M., Flamm, R.K., Tanaka, S.K. J. Clin. Microbiol. (1997)